ImClone, Merck Reach Deal Over Erbitux
New York-based ImClone Systems Inc. and Germany-based Merck KGaA have agreed to amend a 1998 development and licensing agreement that covers the blockbuster cancer drug Erbitux and other epidermal growth factor...To view the full article, register now.
Already a subscriber? Click here to view full article